MENLO PARK, California, July 13, 2026
PharmatrophiX, in collaboration with Indiana University School of Medicine, has presented encouraging new findings demonstrating that its investigational oral therapy LM11A-31 may help preserve brain functional-network connectivity in patients with mild-to-moderate Alzheimer’s disease (AD). The results, unveiled during a Featured Research Session at the Alzheimer’s Association International Conference (AAIC) 2026 in London, highlight the therapy’s potential to slow the deterioration of critical brain communication networks associated with cognition. The analysis utilized an innovative metabolic brain functional-network connectivity mapping technology developed by Indiana University researchers to evaluate changes in brain activity among participants enrolled in the completed Phase 2a clinical trial. The findings showed that LM11A-31 produced statistically significant, dose-dependent improvements in brain network function, supporting its disease-modifying mechanism and strengthening the scientific foundation for advancing the therapy into a planned Phase 2b/3 clinical program.
Novel Brain Imaging Reveals Improved Functional Connectivity
The research team analyzed 18F-FDG-PET brain imaging data from 159 participants enrolled in the randomized Phase 2a clinical trial, comparing placebo, low-dose, and high-dose treatment groups over a 26-week period. Using advanced metabolic covariance analysis, hierarchical clustering, and network efficiency modeling, investigators measured how effectively different brain regions communicated with one another. Results demonstrated that patients receiving LM11A-31, particularly those treated with the 400 mg high-dose regimen, experienced significantly slower declines in whole-brain metabolic connectivity and network efficiency compared with placebo. These improvements were observed in brain regions responsible for memory, learning, executive function, and other cognitive processes, suggesting that the therapy may help preserve the neuronal communication pathways disrupted during Alzheimer’s disease progression. Researchers also identified sex-specific treatment effects, providing additional insight into how disease progression and therapeutic responses may differ between male and female patients.
Disease-Modifying Mechanism Targets Synaptic Resilience
Unlike therapies designed primarily to remove amyloid plaques, LM11A-31 targets the p75 neurotrophin receptor, aiming to preserve synaptic resilience and protect neurons from degeneration. Previous preclinical studies demonstrated that the small-molecule therapy reduces pathological amyloid and tau toxicity, limits abnormal tau accumulation, and decreases harmful activation of microglia and astrocytes, two key drivers of neuroinflammation. Earlier Phase 2a biomarker analyses also reported significant improvements across multiple biological markers, including structural MRI, FDG-PET imaging, cerebrospinal fluid synaptic biomarkers, proteomic signatures, and plasma p-tau217, while patients receiving LM11A-31 showed approximately 50% slower progression on important cognitive assessments such as ADAS-Cog13 and MMSE compared with placebo. Collectively, these findings reinforce the therapy’s potential as a disease-modifying treatment capable of addressing the underlying biology of Alzheimer’s disease rather than simply managing symptoms.
Advertisement
Strong Foundation for Phase 2b/3 Clinical Development
The newly presented functional brain network findings further strengthen the growing body of evidence supporting LM11A-31 as a promising therapeutic candidate for Alzheimer’s disease. Company researchers emphasized that preserving the integrity of brain communication networks may play a critical role in maintaining cognitive function as neurodegeneration progresses. The favorable safety profile reported during the Phase 2a trial, combined with encouraging biomarker, imaging, and cognitive outcomes, provides a strong scientific rationale for advancing the program into a Phase 2b/3 registrational study. As Alzheimer’s disease continues to represent one of the world’s greatest unmet medical challenges, the collaboration between PharmatrophiX and Indiana University demonstrates how innovative imaging technologies, biomarker science, and targeted neuroprotective therapies can accelerate the development of next-generation disease-modifying treatments designed to preserve brain function, slow cognitive decline, and improve outcomes for millions of patients living with neurodegenerative disorders.
Source: PharmatrophiX press release
